Abstracts tagged "Lupus nephritis"

Abstract Number: 2899 • 2019 ACR/ARP Annual Meeting
Transcriptomic Meta-analysis of Lupus Affected Tissues Reveals Shared Immune, Metabolic, and Biochemical Dysregulation
Kathryn Kingsmore¹, Sarah Heuer ¹, Erika Hubbard ¹, Michelle Catalina ², Prathyusha Bachali ², Peter Lipsky ³ and Amrie Grammer ¹, ¹AMPEL BioSolutions and RILITE Research Institute, Charlottesville, VA, ²AMPEL BioSolutions and the RILITE Research Institute, Charlottesville, VA, ³AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Systemic lupus erythematosus (SLE) affects various organs and tissues, but whether pathologic processes in each organ are distinct or whether dysregulated molecular functions are…
Abstract Number: 959 • 2019 ACR/ARP Annual Meeting
A Novel Image Analysis Program, “CytoSkaler”, Demonstrates That Anti-Vimentin Antibody Affinity Maturation in Lupus Tubulointerstitial Nephritis Also Results in More Selective Antigen Targeting
Andrew Kinloch¹, Aazam Mohsin ¹, Yuta Asano ¹, Carole Henry ¹, Nirit Mor Vaknin ², Maureen Legendre ², Patrick Wilson ¹, David Markovitz ² and Marcus Clark ¹, ¹University of Chicago, Chicago, IL, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Vimentin is a dominant target of B-cells selected in lupus tubulointerstial inflammation (TII), a predictor of renal failure. The origins of anti-vimentin antibodies (AVA)…
Abstract Number: 2275 • 2019 ACR/ARP Annual Meeting
Effect of Race and Lupus Nephritis on Pregnancy Outcomes in Systemic Lupus Erythematosus: An Individual Participant Meta-analysis
Ravyn Njagu¹, Amanda Eudy ², Stephen Balevic ³, Michelle Petri ⁴, Dafna Gladman ⁵, Murray Urowitz ⁶ and Megan Clowse ², ¹Duke University, Durham, NC, ²Duke University, Durham, ³Duke University, Hillsborough, NC, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁶University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Individual cohort studies have found that Black and Hispanic women have worse pregnancy outcomes compared to their white counterparts. Additionally, this population of women…
Abstract Number: 62 • 2019 ACR/ARP Annual Meeting
Human Gingiva-derived Mesenchymal Stem Cells Are Therapeutic in Lupus Nephritis Through Targeting of CD39-CD73 Signaling Pathway
Song Guo Zheng¹, Julie Wang ², Junlong dang ³, Nancy Olsen ⁴ and Wael Jarjour ¹, ¹Ohio State College of Medicine, Columbus, OH, ²Ohio State University, columbus, ³Sun Yat-sen University, Guangzhou, ⁴Penn State University, Hershey, PA
Background/Purpose: Cell specific and cytokine targeted therapeutics have underperformed in systemic lupus erythematosus (SLE) in spite of numerous targets examined and clinical trials conducted. Mesenchymal…
Abstract Number: 1018 • 2019 ACR/ARP Annual Meeting
Renal Single Cell Genomics Links Type II Interferon and Lupus Nephritis in African-Americans
Andrea Fava¹, Yuji Zhang ², Jill Buyon ³, Chaim Putterman ⁴, Nir Hacohen ⁵, Arnon Arazi ⁵, Celine Berthier ⁶, Deepak Rao ⁷, Michael Brenner ⁸, David Wofsy ⁹, Anne Davidson ¹⁰, Mathias Kretzler ¹¹, David Hildeman ¹², E. Steve Woodle ¹², Betty Diamond ¹⁰, Thomas Tuschl ¹³, Evan Der ¹⁴, Hemant Suryawanshi ¹³, H. Michael Belmont ¹⁵, Peter Izmirly ¹⁶, Robert Clancy ¹⁶, The Accelerating Medicines Partnership ¹⁷ and Michelle Petri ¹⁸, ¹Johns Hopkins University, Baltimore, ²University of Maryland, Baltimore, ³NYU School of Medicine, New York, ⁴Albert Einstein College of Medicine, New York, NY, ⁵Broad Institute, Cambridge, ⁶University of Michigan, Ann Arbor, MI, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Brigham and Women’s Hospital:, Boston, ⁹UCSF, San Francisco, ¹⁰Feinstein Institutes for Medical Research, Manhasset, ¹¹University of Michigan, Ann Arbor, ¹²University of Cincinnati, Cincinnati, ¹³Rockefeller Research Laboratories, New York, ¹⁴Albert Einstein College of Medicine, New York, ¹⁵New York University School of Medicine, Ney York, ¹⁶New York University School of Medicine, New York, ¹⁷Multiple Organizations, USA, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Compared to Caucasian, African-American ethnicity is associated with a higher risk of developing systemic lupus erythematosus, lupus nephritis, high-risk histological features, resistance to treatment,…
Abstract Number: 2528 • 2019 ACR/ARP Annual Meeting
Effect of Additional Administration of HCQ on Pro-inflammatory Cytokine Expression, Especially in Lupus Nephritis
Risa Wakiya¹, Kiyo Ueeda ², Hiromi Shimada ², Shusaku Nakashima ¹, Mai Mahmoud Fahmy Mansour ¹, Mikiya Kato ¹, Taichi Miyagi ¹, Tomohiro Kameda ¹ and Hiroaki Dobashi ², ¹Kagawa University, Kagawa, ²Kagawa University, Kagawa, Japan
Background/Purpose: Hydroxychloroquine(HCQ) is recommended for all patients with SLE in EULAR recommendation 2019, however, there are not enough data about the effect of additional HCQ…
Abstract Number: 65 • 2019 ACR/ARP Annual Meeting
CD6 Modulation Ameliorates Skin and Kidney Disease in a Spontaneous Murine Model of SLE
Samantha Chalmers¹, Sayra Garcia ¹, Rajalakshmy Ayilam Ramachandran ², Chandra Mohan ², Jeanette Ampudia ³, Cherie Ng ³, Stephen Connelly ³ and Chaim Putterman ⁴, ¹Albert Einstein College of Medicine, Bronx, NY, ²University of Houston, Houston, ³Equillium, Inc, San Diego, CA, ⁴Albert Einstein College of Medicine, New York, NY
Background/Purpose: T cells are an important contributor the pathogenesis of SLE and its various end organ manifestations. Thus, they present themselves as potential therapeutic targets;…
Abstract Number: 1128 • 2019 ACR/ARP Annual Meeting
Physician-Patient Interaction and Medication Adherence in Lupus Nephritis
Sofia Georgopoulou¹, Louise Nel ², Shirish Sangle ² and David D'Cruz ³, ¹King's College London & The Royal Marsden Hospital NHS Foundation Trust, London, England, United Kingdom, ²Guy's & St Thomas' Hospitals NHS Foundation Trust, London, England, United Kingdom, ³The Louise Coote Lupus Unit, Guy's Hospital, London, England, United Kingdom
Background/Purpose: The quality of physician-patient interaction can have a significant impact on medication adherence. Little is known about this relationship in patients with lupus nephritis…
Abstract Number: 2542 • 2019 ACR/ARP Annual Meeting
An Updated Meta-Analysis of the Efficacy and Safety of Mycophenolate Mofetil in the Induction Treatment of Chinese Patients with Lupus Nephritis
Minlin Zhou¹, Yang yang ², Xiaoyan Han ², Xin Yu ² and Haitao zhang ¹, ¹National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China (People's Republic), ²Shanghai Roche Pharmaceuticals Ltd, Shanghai, China (People's Republic)
Background/Purpose: Achieving clinical remission while reducing toxicity are primary objectives in the treatment of lupus nephritis (LN). Mycophenolate mofetil (MMF) has demonstrated efficacy benefits with…
Abstract Number: 66 • 2019 ACR/ARP Annual Meeting
Amelioration of Immune Complex-Mediated Glomerulonephritis by CD6 Modulation
Samantha Chalmers¹, Sayra Garcia ¹, Jeanette Ampudia ², Cherie Ng ², Stephen Connelly ² and Chaim Putterman ³, ¹Albert Einstein College of Medicine, Bronx, NY, ²Equillium, Inc, San Diego, CA, ³Albert Einstein College of Medicine, New York, NY
Background/Purpose: CD6 is a co-stimulatory receptor on T cells, that binds to activated leukocyte cell adhesion molecule (ALCAM), a ligand expressed on antigen presentation cells…
Abstract Number: 1564 • 2019 ACR/ARP Annual Meeting
Renal Arteriosclerosis Predicts Cardiovascular Disease in Lupus Nephritis
Shivani Garg¹, Sarah Panzer ², Karen Hansen ³, Callie Plafkin ⁴, Maureen Smith ² and Christie Bartels ¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²UW-Madison, Madison, ³UW Madison, Madison, ⁴UW Health, Madison
Background/Purpose: Patients with lupus nephritis (LN) have a 9-fold higher risk of cardiovascular disease (CVD), highlighting the urgent need to target CVD prevention. Studies in…
Abstract Number: 2556 • 2019 ACR/ARP Annual Meeting
Histologic Findings from Paired Renal Biopsies and Clinical Outcomes: Results from a Single Site in the Phase III Study of Abatacept in Patients with Proliferative LN
Ana Malvar¹, Valeria Alberton ², Cecilia Recalde ², Sheng Gao ³ and Michael Maldonado ³, ¹Hospital Fernandez; Organización Maedica de Investigación, Buenos Aires, Argentina, ²Hospital Fernandez, Buenos Aires, Argentina, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Current therapeutic management of active Class III or IV proliferative LN relies on the use of maintenance therapy following induction. The optimal method for…
Abstract Number: 72 • 2019 ACR/ARP Annual Meeting
The Single-cell Transcriptomic Landscape of NZB/W Murine Lupus at Early and Late Stages of Disease
Paul Hoover¹, Tom Eisenhaure ², David Lieb ², Anne Davidson ³ and Nir Hacohen ², ¹Brigham and Women's Hospital, Boston, MA, ²Broad Institute, Cambridge, MA, ³Feinstein Institutes for Medical Research, Manhasset
Background/Purpose: Lupus nephritis is a complex and heterogeneous disease characterized by infiltrating immune cells in damaged kidney tissue. While mouse models have enabled mechanistic studies…
Abstract Number: 1566 • 2019 ACR/ARP Annual Meeting
HER2 as a Biomarker of Proliferative Lupus Nephritis in Children
Kathleen Sullivan¹, Jonathan Burnham ², Kathleen O'Neil ³, Laura Schanberg ⁴, Emily von Scheven ⁵, Marisa Klein-Gitelman ⁶ and Patricia Costa Reis ⁷, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²The Children's Hospital of Philadelphia, Philadelphia, PA, ³Indiana University, Indianapolis, IN, ⁴Duke University Medical Center, Durham, NC, ⁵UCSF, San Francisco, CA, ⁶Lurie Children's Hospital, Chicago, IL, ⁷Hospital de Santa Maria, Lisbon, Portugal
Background/Purpose: Lupus nephritis is a common feature of SLE and confers a poor prognosis. 20-50% of patients with lupus nephritis ultimately develop chronic kidney disease…
Abstract Number: 2561 • 2019 ACR/ARP Annual Meeting
Deep Remission During Induction Therapy for Lupus Nephritis Prevents Damage Accrual and Associates with the Baseline Proportions of Peripheral Treg, CD8+ T Cells, and NKT-like Cells
Jun Kikuchi¹, Hironari Hanaoka ¹, Shuntaro Saito ¹, Tatsuhiro Oshige ¹, Kazuoto Hiramoto ¹, Yuko Kaneko ¹, Noriyasu Seki ², Hideto Tsujimoto ² and Tsutomu Takeuchi ¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Mitsubishi Tanabe Pharma Corporation Sohyaku. Innovative Research Division, Toda-shi, Saitama, Japan
Background/Purpose: chievement of renal remission has been the target of the induction therapy in patients with active lupus nephritis (LN). Deep remission (DR) defined as…

« Previous Page
1
…
4
5
6
7
8
…
16
Next Page »